On 6 July 2026, JW Therapeutics (Cayman) Co. Ltd filed its monthly return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, confirming that key equity metrics remained unchanged during the month.

Authorised and Issued Capital • Authorised share capital stayed at 5.00 billion ordinary shares with a par value of USD 0.00001, equivalent to USD 50,000. • Issued shares were unchanged at 416.73 million, and the company continued to hold no treasury shares.

Public Float • The company reconfirmed compliance with the Main Board’s minimum 25% public-float requirement.

Share Option Activity • No new shares were issued through option exercises; consequently, no funds were raised. • Two option grants recorded lapses—225,000 options (HK$1.48 exercise price, April 2025 grant) and 80,000 options (HK$2.52 exercise price, April 2026 grant). • After these adjustments, 22.77 million options remain outstanding across pre-IPO and post-IPO schemes, with exercise prices ranging from US$0.00001 to HK$16.20. • The post-IPO scheme still permits up to 3.67 million additional options to be granted.

Restricted Share Units • The 2019 Restricted Share Unit Scheme carried an unissued balance of 1.20 million shares; no RSUs were granted or vested in June.

Other Securities • The company reported no outstanding warrants, convertible instruments, or other equity-linked agreements beyond the disclosed option and RSU schemes.

Overall, JW Therapeutics recorded no changes in share capital during June 2026, maintained full public-float compliance, and saw limited activity confined to option lapses.